Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

BenevolentAI: using artificial intelligence to speed up drug discovery

British artificial intelligence company BenevolentAI recently signed an exclusive license agreement for a series of novel clinical stage drug candidates with Johnson & Johnson. Their potential was evaluated using the company’s unique AI technology, which, if the compounds prove successful, could hail a significant breakthrough in the way drugs are developed. Abi Millar spoke to the company to find out more.


Go Top